We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
- Authors
Zhu, Andrew X; Clark, Jeffrey W; Ryan, David P; Meyerhardt, Jeffrey A; Enzinger, Peter C; Earle, Craig C; Fuchs, Charles S; Regan, Eileen; Anbe, Hiroshi; Houghton, Michele; Zhang, Joshua; Urrea, Peter; Kulke, Matthew H
- Abstract
S-1 is a novel oral fluoropyrimidine that combines tegafur with CDHP and oxonic acid. To decrease the incidence of late onset, severe diarrhea observed in a previous study, a phase I study was conducted to determine the maximum tolerated dose (MTD) of S-1 utilizing a 14-day schedule, repeated every 21 days, in patients with chemotherapy-refractory upper gastrointestinal malignancies.
- Publication
Cancer chemotherapy and pharmacology, 2007, Vol 59, Issue 3, p285
- ISSN
0344-5704
- Publication type
Journal Article
- DOI
10.1007/s00280-006-0265-y